Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £538.27m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Director/PDMR Shareholding

4 Oct 2010 09:45

RNS Number : 7863T
Allergy Therapeutics PLC
04 October 2010
 



Allergy Therapeutics PLC

4 October 2010

 



Monday 4 October 2010

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

Major Shareholdings/Holding by Director

 

 

Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specializing in allergy vaccines announces today that 137,491,788 of its ordinary shares were transferred on 28 September 2010 by Azure Ventures Limited to Yissum Holdings Limited a company controlled by members of the Weinstein family, including Mr Alejandro Weinstein Jr, a non-executive director of the Company. Notification of the transfer was received by the Company on 4 October 2010. There has been no change in the aggregate beneficial holding of shares in the Company by the Weinstein family.

 

 

The Karjiang Pharma Trust, of which the Weinstein family, including Mr Alejandro Weinstein Jr., are beneficiaries, continues to hold 3,076,499 shares in the Company, through Azure Ventures Limited. As a result of the transfer the percentage of voting rights controlled by the Karjiang Pharma Trust has fallen from 45.23 per cent. to below 3 per cent.

 

Yissum Holdings Limited, a company which is controlled by the Weinstein family, including Mr Alejandro Weinstein Jr., now holds 137,491,788 shares in the Company, representing 44.24 per cent. of the Company's total voting rights.

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Ian Postlethwaite, Finance Director

www.allergytherapeutics.com

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Christopher Golden

www.nomuracode.com

 

Financial Dynamics

+44 (0) 207 831 3113

Ben Brewerton/ Susan Quigley

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGIBDGXSGBGGS
Date   Source Headline
26th Jun 20239:25 amRNSForm 8.5 (EPT/RI)
23rd Jun 202311:48 amRNSForm 8.5 (EPT/RI)
23rd Jun 202310:48 amBUSForm 8.3 - The Allergy Therapeutics Plc
22nd Jun 20239:55 amBUSForm 8.3 - THE ALLERGY THERAPEUTICS PLC
22nd Jun 20238:45 amRNSForm 8.5 (EPT/RI)
21st Jun 20239:38 amRNSForm 8.5 (EPT/RI)
20th Jun 202312:49 pmRNSForm 8.5 - Allergy Therapeutics plc
20th Jun 20239:57 amBUSForm 8.3 - The Allergy Therapeutics Plc
20th Jun 20239:05 amRNSForm 8.5 (EPT/RI)
19th Jun 20237:30 amRNSRestoration - Allergy Therapeutics PLC
19th Jun 20237:01 amRNSInterim Results and Lifting Suspension in Trading
19th Jun 20237:00 amRNSPublication of Annual Report and Accounts 2022
9th Jun 20237:00 amRNSAllergy Therapeutics shares key findings at EAACI
3rd May 20239:09 amRNSForm 8.3 - Allergy Therapeutics plc
27th Apr 20232:15 pmRNSResult of General Meeting
24th Apr 20237:00 amRNSSouthern Fox: Form 8.3 – Allergy Therapeutics Plc
21st Apr 20237:00 amRNSFORM 8 (OPD) – Allergy Therapeutics plc
20th Apr 20235:29 pmRNSProject Zebra Rule 2.9 Announcement
19th Apr 20237:00 amRNSSkin-prick testing completes in PROTECT Trial
17th Apr 20232:30 pmRNSForm 8 OPD SkyGem Acquisition Limited Replacement
17th Apr 202310:30 amRNSForm 8 (OPD) SkyGem Acquisition Limited
11th Apr 202310:10 amBUSForm 8.3 - The Allergy Therapeutics Plc
6th Apr 20232:01 pmRNSStatement Regarding Possible Mandatory Cash Offer
6th Apr 20232:01 pmRNS£40.75 million Facility with Equity Financing
6th Apr 20232:00 pmRNSTrading and Business Update
29th Mar 20237:00 amRNSPublication of Interim Results Delayed
27th Mar 20237:00 amRNSPatients dosed in VLP Peanut PROTECT trial
8th Mar 20235:28 pmRNSBlock Listing Interim Review
3rd Mar 20237:00 amRNSPDMR Dealing
7th Feb 20236:29 pmRNSResult of AGM
20th Jan 20237:00 amRNSHalf-Year Trading Update 2023
13th Jan 20235:27 pmRNSNOTICE OF 2022 ANNUAL GENERAL MEETING
3rd Jan 20237:30 amRNSSuspension - Allergy Therapeutics plc
29th Dec 202211:05 amRNSSecond Price Monitoring Extn
29th Dec 202211:00 amRNSPrice Monitoring Extension
29th Dec 20229:05 amRNSSecond Price Monitoring Extn
29th Dec 20229:00 amRNSPrice Monitoring Extension
29th Dec 20227:00 amRNSAnnual Report and Accounts Delayed
28th Dec 20227:00 amRNSDirector Resignation
8th Dec 20227:00 amRNSKey updates on Grass MATA MPL and VLP Peanut
6th Dec 20227:00 amRNSAppointment of Non-Executive Directors
21st Nov 20227:00 amRNSAppointment of Interim CFO
28th Oct 20227:00 amRNSAllergy to resume UK manufacturing production
19th Oct 20223:39 pmRNSHolding(s) in Company
17th Oct 20221:27 pmRNSAllergy Therapeutics – Result of GM
4th Oct 20227:00 amRNSUK manufacturing update
29th Sep 202212:00 pmRNSAllergy Therapeutics at Investor Meet Company
29th Sep 20227:00 amRNSSubscription and Debt Financing
29th Sep 20227:00 amRNSUnaudited Preliminary Results 2022
5th Sep 20227:00 amRNSAllergy Therapeutics at H.C. Wainwright Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.